Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07298083 · ClinicalTrials.gov registry record
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 60
- Enrollment target
NCT07298083: Recruiting study, sponsored by M.D. Anderson Cancer Center.
NCT07298083 is a clinical trial that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07298083 is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-04-02 |
| Est. Completion | 2032-04-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07298083
The ClinicalTrials.gov registry entry for NCT07298083 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07298083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07298083 about?
NCT07298083 is a clinical study titled "DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins". The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.
What is the current status of trial NCT07298083?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2026-04-02. Estimated completion is 2032-04-20.
Who is sponsoring clinical trial NCT07298083?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.